Sun Pharma bought Ranbaxy for $4 billion. The CCI let it through — but only after ordering the parties to divest seven products first, and it barred the merger from taking effect until they had.
Cross the Section 5 asset or turnover thresholds, or the ₹2,000 crore deal value threshold with substantial business operations in India, and you must notify the CCI and wait. Closing before approval is gun-jumping, penalised up to 1% of total turnover or assets.
Sections 5 and 6 of the Competition Act, 2002 create what lawyers call a suspensory merger control regime — meaning the deal stays suspended until the regulator clears it. A transaction that must be notified cannot be completed until the CCI approves it or the statutory period runs out. This is not a filing you make on the way to closing. It is something you must finish before you are allowed to close.
Throughout this article, one test does the heavy lifting: whether a deal causes an Appreciable Adverse Effect on Competition (AAEC) in India — in plain terms, whether it meaningfully harms competition, by removing a real rival, concentrating a market, or making it harder for others to enter.
The Competition (Amendment) Act, 2023, operationalised through the CCI (Combinations) Regulations, 2024 with effect from 10 September 2024, reshaped the regime: it added a deal value threshold to catch asset-light digital acquisitions that slipped past turnover tests, codified "material influence" as the control standard, and compressed review timelines from 210 days to 150 days.
BOTTOM LINE
- Notify if the parties cross the Section 5 asset/turnover thresholds, or the transaction value exceeds ₹2,000 crore and the target has substantial business operations in India.
- De minimis exemption: small targets (by assets and turnover in India) are exempt — but not where the deal value threshold applies.
- You must wait: the deal cannot be completed until approval. Closing early is called gun-jumping, penalised up to 1% of total turnover or assets, whichever is higher.
- Timelines: a first-look review within 30 calendar days; if the CCI passes no order within 150 days, approval is treated as granted.
- Control standard: now expressly "material influence" — the lowest threshold, well below majority.
When must you notify?
Governs this section: Sections 5 & 6, Competition Act, 2002; CCI (Combinations) Regulations, 2024
A combination is an acquisition of control, shares, voting rights or assets, an acquisition of control by a person over an enterprise where that person already controls a competing enterprise, or a merger or amalgamation — where the parties cross the prescribed thresholds.
The asset/turnover thresholds (Section 5) operate at two levels — the parties to the transaction, and the group to which the target will belong — and in two geographies, India and worldwide (with an India leg). The figures are periodically revised by Central Government notification and enhanced by inflation-linked adjustments, so the current notification must always be checked rather than assumed.
The deal value threshold (DVT). Introduced by the 2023 Amendment and operative from 10 September 2024: a transaction requires CCI approval where:
- the value of the transaction exceeds ₹2,000 crore — including direct, indirect, immediate and deferred consideration; and
- the target has "substantial business operations in India" (SBOI).
The Combinations Regulations, 2024 define SBOI by reference to India-linked metrics — for digital-sector targets, thresholds tied to India users, subscribers or business users as a proportion of global figures; for other sectors, broadly where the target's India turnover in the preceding financial year exceeds 10% of its global turnover. The DVT exists because acquisitions of user-rich, revenue-poor technology targets — the archetype being a messaging platform with hundreds of millions of users and negligible turnover — escaped the traditional tests entirely.
The small target exemption (lawyers call it the de minimis exemption — "too small to matter"). Where the target's India assets and India turnover fall below notified levels, no filing is needed. Critically, this exemption does not rescue a transaction that meets the deal value threshold — a company with few assets but substantial India operations must still be notified, however small its balance sheet.
CAUTION — "control" is now material influence
The 2023 Amendment codified control as "material influence" — the ability to materially influence the management, affairs or strategic commercial decisions of an enterprise. This is the lowest of the recognised control standards, below de facto control and far below majority ownership. Board observer seats, veto rights over the business plan or budget, and significant minority stakes with special rights can all constitute material influence. A minority investment you regard as passive may be a notifiable acquisition of control.
The process and timelines
Governs this section: Sections 6, 29, 30 & 31, Competition Act, 2002
- Notification in Form I (short form) or Form II (long form, for higher-overlap transactions) after the trigger document is executed.
- Phase I: within 30 calendar days, the CCI forms a first-look view (a prima facie opinion) on whether the deal harms or is likely to harm competition. Most transactions clear here.
- Phase II (Section 29): if that first look raises a concern, the CCI issues a show-cause notice, may call for a report from the Director General (its investigating arm), and requires the parties to publish details of the combination for public comment — inviting objections from competitors, customers and industry bodies.
- Modifications (Section 31): the CCI may approve subject to modifications it proposes under Section 31(3) — typically structural (divestitures) or behavioural (access, pricing, firewall commitments). Parties may propose amendments to the CCI's proposed modification under Section 31(6); if the Commission accepts, approval issues under Section 31(7).
- Outer limit: deemed approval if the CCI passes no order within 150 days (reduced from 210 by the 2023 Amendment).
Gun-jumping — closing too early
Governs this section: Sections 6(2A) & 43A, Competition Act, 2002
Section 6(2A) prohibits completing a notifiable deal before approval or expiry of the statutory period. Section 43A penalises breach — failure to notify, or completing the deal before approval — with a penalty of up to 1% of the total turnover or assets, whichever is higher, of the combination.
Gun-jumping is rarely a deliberate defiance. It happens through:
- partial closing — completing one leg of an interdependent, step-transaction before approval;
- exercising rights early — appointing directors, taking board seats, or exercising veto rights before clearance;
- integration in advance — sharing competitively sensitive information, aligning pricing, or combining sales teams during the review period;
- failing to notify at all, on an incorrect view that a threshold was not met or an exemption applied.
The 2023 Amendment carved out a relaxation from this wait-and-hold requirement for certain stock-market purchases — open-market acquisitions may proceed subject to conditions including that voting rights are not exercised pending approval — which relieves a genuine practical problem for public-market transactions.
The Sun Pharma–Ranbaxy case
Governs this section: CCI order dated 5 December 2014, Combination Registration No. C-2014/05/170
This is the definitive Indian merger-control case study, and the CCI's first-ever Phase II review.
The transaction. In April 2014, Sun Pharmaceutical Industries announced the acquisition of Ranbaxy Laboratories by way of merger, in a transaction valued at roughly $4 billion — creating India's largest and the world's fifth-largest generic pharmaceutical company. Notice was filed with the CCI on 6 May 2014.
Why it went to Phase II. Both parties were primarily generics manufacturers with overlapping portfolios across numerous molecules. Assessing combined market share, incremental share, competitor strength and market structure, the CCI took the view that competition was likely to be harmed in several specific markets — in some, the merger would reduce the effective number of players from three to two. In September 2014 the CCI formally escalated to Phase II, and — for the first time in Indian merger control — required the parties to publish details of the combination for public scrutiny and comment.
The remedy. By letter dated 27 November 2014 the CCI proposed modifications under Section 31(3). The parties responded on 4 December proposing amendments under Section 31(6) — notably, in the market for products containing Leuprorelin, asking that Ranbaxy divest its Eligard distribution rights instead of Sun Pharma divesting its Lupride brand. The CCI accepted this amendment, noting that Ranbaxy held only distribution rights in that market and that divesting them would effectively eliminate the competitive concern — while building in a safeguard: if the Eligard divestiture was not achieved within the first divestiture period, Sun Pharma would have to divest Lupride instead.
On 5 December 2014 the CCI approved the combination under Section 31(7) subject to divestiture of products across seven relevant markets — Sun Pharma divesting all products containing Tamsulosin + Tolterodine (marketed as Tamlet), and Ranbaxy divesting six products. In the markets concerned, the parties' combined share ran as high as 90–95%. The CCI further directed that the merger should not take effect until the divestitures were carried out, and appointed a monitoring agency to oversee compliance.
Why it matters.
- Phase II is real. For years practitioners treated Indian merger control as a formality. Sun–Ranbaxy established that the CCI will open a full review, invite public objections, and hold up a marquee transaction.
- Remedies are negotiated, not dictated. The Section 31(6) mechanism let the parties reshape the remedy — substituting a distribution-rights divestiture for a brand divestiture — and the CCI accepted it because the competitive effect was equivalent. Engagement produces better outcomes than resistance.
- Product-level, not deal-level, analysis. A $4 billion merger was cleared on the strength of divesting a handful of overlapping products. The CCI's unit of analysis is the relevant market, and a large deal with narrow overlaps is often more approvable than a small deal with a deep one.
- Closing can be conditioned on remedy completion. The direction that the merger not take effect before divestiture is a powerful structural tool — and a timetable risk that transaction documents must accommodate.
PRACTITIONER'S NOTE — model the remedy before you sign
The Sun–Ranbaxy sequence took roughly seven months from notification to conditional approval, and closing was further gated on completing divestitures. Where portfolios overlap meaningfully, the parties should map likely problem markets before signing, pre-identify divestible assets, and negotiate long-stop dates and risk allocation accordingly. A merger agreement drafted on the assumption of a 30-day clearance is a drafting failure, not a regulatory surprise.
Other combination precedents worth knowing
Governs this section: CCI combination practice
Holcim–Lafarge (CCI, 2015). The CCI's second Phase II review, following immediately after Sun–Ranbaxy. It required divestiture of cement plants to address overlaps, and established that the CCI would scrutinise the identity and viability of the purchaser of divested assets — a remedy is only effective if the buyer can actually compete.
Gun-jumping penalties. The CCI has repeatedly imposed Section 43A penalties for failure to notify and for closing too early, including where parties treated linked steps of one deal as if they were separate, or where an acquirer exercised board rights during the review period. These orders — rather than any single leading judgment — define the practical boundary of the duty to wait.
Worked example
Mini-case — the ₹2,400 crore acquisition of a loss-making platform
A global technology group agrees to acquire an Indian consumer app for ₹2,400 crore. The target has 40 million Indian users, negligible revenue and almost no assets.
Under the old regime: the target's India assets and turnover fall well below the small-target levels. No filing required. The transaction closes.
Under the current regime: the deal value exceeds ₹2,000 crore, and with 40 million Indian users the target plainly has substantial business operations in India under the digital-sector SBOI test. The transaction is notifiable, the small-target exemption does not apply, and the parties must file and wait.
If they close anyway: Section 43A exposure of up to 1% of the combination's total turnover or assets — computed on the acquiring group's figures, not the tiny target's. On a large multinational acquirer, that is a penalty measured in hundreds of crore for a transaction the parties believed was exempt.
The compounding risk: if the acquirer also takes board seats or exercises veto rights at signing, that is independent gun-jumping conduct even if a filing is later made.
Common mistakes
- Assuming the small-target exemption always saves a small target. It does not apply where the deal value threshold is met.
- Testing only asset and turnover thresholds and ignoring the ₹2,000 crore DVT.
- Under-reading "control". The standard is material influence — board observer rights and strategic vetoes can trigger it.
- Closing an interdependent step transaction in parts before approval.
- Integrating during review — sharing competitively sensitive information, aligning pricing, combining teams.
- Exercising board or voting rights before clearance.
- Excluding deferred or contingent consideration when computing transaction value — the DVT includes it.
- Assuming a 30-day clearance in the transaction timetable where overlaps are material.
- Failing to pre-identify divestible assets in an overlapping-portfolio deal.
Checklist
- Test all three gateways: Section 5 asset/turnover thresholds, the ₹2,000 crore deal value threshold with substantial India operations, and the small-target exemption.
- Compute transaction value inclusive of direct, indirect, immediate and deferred consideration.
- Assess whether rights acquired amount to material influence, even in a minority investment.
- Map product and geographic overlaps early; identify likely problem markets and divestible assets.
- Choose Form I or Form II based on overlap levels; prepare for public scrutiny if Phase II is likely.
- Build the standstill into the transaction documents — no board seats, no integration, no rights exercise pending approval.
- Establish clean-team protocols governing information exchange during review.
- Set long-stop dates realistically: 30 days for a clean Phase I; several months plus remedy implementation where overlaps are material.
- Where remedies are likely, engage under Section 31(6) with a workable alternative rather than contesting the concern.
FAQ
When must a transaction be notified to the CCI? When the Section 5 asset or turnover thresholds are crossed, or the transaction value exceeds ₹2,000 crore and the target has substantial business operations in India.
What is the deal value threshold? A ₹2,000 crore transaction-value test introduced by the 2023 Amendment, operative from 10 September 2024, designed to capture asset-light digital acquisitions that escaped turnover-based tests.
What is gun-jumping and what does it cost? Consummating a notifiable combination before approval, or failing to notify. Section 43A penalty: up to 1% of the total turnover or assets of the combination, whichever is higher.
How long does CCI approval take? A first-look view is formed within 30 calendar days. If the CCI passes no order within 150 days, approval is treated as granted.
Can the CCI block a merger outright? Yes, under Section 31(2) where it harms competition in a way that cannot be fixed by conditions — though in practice the CCI has preferred approval with modifications, as in Sun Pharma–Ranbaxy.
What happened in the Sun Pharma–Ranbaxy case? The CCI's first Phase II review. It approved the $4 billion merger on 5 December 2014 subject to divestiture of products across seven relevant markets, directed that the merger not take effect until divestitures were completed, and appointed a monitoring agency.
Does a minority investment need notification? It can — if it confers material influence over management, affairs or strategic commercial decisions, or if the thresholds are otherwise met.
Primary sources
- Sections 5, 6, 6(2A), 20, 29, 30, 31 & 43A, Competition Act, 2002
- Competition (Amendment) Act, 2023
- CCI (Combinations) Regulations, 2024, effective 10 September 2024
- Ministry of Corporate Affairs notifications on Section 5 thresholds and exemptions
- CCI order dated 5 December 2014 in Combination Registration No. C-2014/05/170 (Sun Pharmaceutical Industries Limited / Ranbaxy Laboratories Limited), and order dated 17 March 2015
- CCI orders in the Holcim/Lafarge combination (2015)
Disclaimer: This article is general information on a fast-changing area of competition law, current at the time of writing. Section 5 thresholds are revised periodically by Government notification and must be verified against the current position before any filing decision. Case summaries are simplified for awareness. This is not legal advice — consult competition counsel before signing or closing any transaction.